201 related articles for article (PubMed ID: 34975752)
21. [The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].
Jiang XB; Hu B; Fan X; He DS; Mao ZG; Chen M; Zhu YH; Wang HJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 May; 44(3):462-5. PubMed ID: 23898536
[TBL] [Abstract][Full Text] [Related]
22. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
23. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
25. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
26. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
28. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.
Bush ZM; Longtine JA; Cunningham T; Schiff D; Jane JA; Vance ML; Thorner MO; Laws ER; Lopes MB
J Clin Endocrinol Metab; 2010 Nov; 95(11):E280-90. PubMed ID: 20668043
[TBL] [Abstract][Full Text] [Related]
30. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
31. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.
Das L; Rai A; Salunke P; Ahuja CK; Sood A; Radotra BD; Sood R; Korbonits M; Dutta P
J Endocr Soc; 2022 Feb; 6(2):bvab190. PubMed ID: 35059545
[TBL] [Abstract][Full Text] [Related]
35. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
36. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
38. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
39. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
Chen W; Xiao Z; Zhao Y; Huang L; Du G
Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
[TBL] [Abstract][Full Text] [Related]
40. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
